Research ExplorerPublicationsPredictive and prognostic value of tumor volume and its chan...

Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: A systematic review

Standard

Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: A systematic review. / Käsmann, Lukas; Niyazi, Maximilian; Blanck, Oliver; Baues, Christian; Baumann, René; Dobiasch, Sophie; Eze, Chukwuka; Fleischmann, Daniel; Gauer, Tobias; Giordano, Frank A; Goy, Yvonne; Hausmann, Jan; Henkenberens, Christoph; Kaul, David; Klook, Lisa; Krug, David; Mäurer, Matthias; Panje, Cédric M; Rosenbrock, Johannes; Sautter, Lisa; Schmitt, Daniela; Süß, Christoph; Thieme, Alexander H; Trommer-Nestler, Maike; Ziegler, Sonia; Ebert, Nadja; Medenwald, Daniel; Ostheimer, Christian; Young DEGRO Group.

In: STRAHLENTHER ONKOL, Vol. 194, No. 2, 02.2018, p. 79-90.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Käsmann, L, Niyazi, M, Blanck, O, Baues, C, Baumann, R, Dobiasch, S, Eze, C, Fleischmann, D, Gauer, T, Giordano, FA, Goy, Y, Hausmann, J, Henkenberens, C, Kaul, D, Klook, L, Krug, D, Mäurer, M, Panje, CM, Rosenbrock, J, Sautter, L, Schmitt, D, Süß, C, Thieme, AH, Trommer-Nestler, M, Ziegler, S, Ebert, N, Medenwald, D, Ostheimer, C & Young DEGRO Group 2018, 'Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: A systematic review', STRAHLENTHER ONKOL, vol. 194, no. 2, pp. 79-90. https://doi.org/10.1007/s00066-017-1221-y

APA

Käsmann, L., Niyazi, M., Blanck, O., Baues, C., Baumann, R., Dobiasch, S., Eze, C., Fleischmann, D., Gauer, T., Giordano, F. A., Goy, Y., Hausmann, J., Henkenberens, C., Kaul, D., Klook, L., Krug, D., Mäurer, M., Panje, C. M., Rosenbrock, J., ... Young DEGRO Group (2018). Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: A systematic review. STRAHLENTHER ONKOL, 194(2), 79-90. https://doi.org/10.1007/s00066-017-1221-y

Vancouver

Käsmann L, Niyazi M, Blanck O, Baues C, Baumann R, Dobiasch S et al. Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: A systematic review. STRAHLENTHER ONKOL. 2018 Feb;194(2):79-90. https://doi.org/10.1007/s00066-017-1221-y

Bibtex

@article{10634e1b8dea4968ad73e46e461b8379,
title = "Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: A systematic review",
abstract = "PURPOSE: Lung cancer remains the leading cause of cancer-related mortality worldwide. Stage III non-small cell lung cancer (NSCLC) includes heterogeneous presentation of the disease including lymph node involvement and large tumour volumes with infiltration of the mediastinum, heart or spine. In the treatment of stage III NSCLC an interdisciplinary approach including radiotherapy is considered standard of care with acceptable toxicity and improved clinical outcome concerning local control. Furthermore, gross tumour volume (GTV) changes during definitive radiotherapy would allow for adaptive replanning which offers normal tissue sparing and dose escalation.METHODS: A literature review was conducted to describe the predictive value of GTV changes during definitive radiotherapy especially focussing on overall survival. The literature search was conducted in a two-step review process using PubMed{\textregistered}/Medline{\textregistered} with the key words {"}stage III non-small cell lung cancer{"} and {"}radiotherapy{"} and {"}tumour volume{"} and {"}prognostic factors{"}.RESULTS: After final consideration 17, 14 and 9 studies with a total of 2516, 784 and 639 patients on predictive impact of GTV, GTV changes and its impact on overall survival, respectively, for definitive radiotherapy for stage III NSCLC were included in this review. Initial GTV is an important prognostic factor for overall survival in several studies, but the time of evaluation and the value of histology need to be further investigated. GTV changes during RT differ widely, optimal timing for re-evaluation of GTV and their predictive value for prognosis needs to be clarified. The prognostic value of GTV changes is unclear due to varying study qualities, re-evaluation time and conflicting results.CONCLUSION: The main findings were that the clinical impact of GTV changes during definitive radiotherapy is still unclear due to heterogeneous study designs with varying quality. Several potential confounding variables were found and need to be considered for future studies to evaluate GTV changes during definitive radiotherapy with respect to treatment outcome.",
keywords = "Journal Article",
author = "Lukas K{\"a}smann and Maximilian Niyazi and Oliver Blanck and Christian Baues and Ren{\'e} Baumann and Sophie Dobiasch and Chukwuka Eze and Daniel Fleischmann and Tobias Gauer and Giordano, {Frank A} and Yvonne Goy and Jan Hausmann and Christoph Henkenberens and David Kaul and Lisa Klook and David Krug and Matthias M{\"a}urer and Panje, {C{\'e}dric M} and Johannes Rosenbrock and Lisa Sautter and Daniela Schmitt and Christoph S{\"u}{\ss} and Thieme, {Alexander H} and Maike Trommer-Nestler and Sonia Ziegler and Nadja Ebert and Daniel Medenwald and Christian Ostheimer and {Young DEGRO Group}",
year = "2018",
month = feb,
doi = "10.1007/s00066-017-1221-y",
language = "English",
volume = "194",
pages = "79--90",
journal = "STRAHLENTHER ONKOL",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "2",

}

RIS

TY - JOUR

T1 - Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: A systematic review

AU - Käsmann, Lukas

AU - Niyazi, Maximilian

AU - Blanck, Oliver

AU - Baues, Christian

AU - Baumann, René

AU - Dobiasch, Sophie

AU - Eze, Chukwuka

AU - Fleischmann, Daniel

AU - Gauer, Tobias

AU - Giordano, Frank A

AU - Goy, Yvonne

AU - Hausmann, Jan

AU - Henkenberens, Christoph

AU - Kaul, David

AU - Klook, Lisa

AU - Krug, David

AU - Mäurer, Matthias

AU - Panje, Cédric M

AU - Rosenbrock, Johannes

AU - Sautter, Lisa

AU - Schmitt, Daniela

AU - Süß, Christoph

AU - Thieme, Alexander H

AU - Trommer-Nestler, Maike

AU - Ziegler, Sonia

AU - Ebert, Nadja

AU - Medenwald, Daniel

AU - Ostheimer, Christian

AU - Young DEGRO Group

PY - 2018/2

Y1 - 2018/2

N2 - PURPOSE: Lung cancer remains the leading cause of cancer-related mortality worldwide. Stage III non-small cell lung cancer (NSCLC) includes heterogeneous presentation of the disease including lymph node involvement and large tumour volumes with infiltration of the mediastinum, heart or spine. In the treatment of stage III NSCLC an interdisciplinary approach including radiotherapy is considered standard of care with acceptable toxicity and improved clinical outcome concerning local control. Furthermore, gross tumour volume (GTV) changes during definitive radiotherapy would allow for adaptive replanning which offers normal tissue sparing and dose escalation.METHODS: A literature review was conducted to describe the predictive value of GTV changes during definitive radiotherapy especially focussing on overall survival. The literature search was conducted in a two-step review process using PubMed®/Medline® with the key words "stage III non-small cell lung cancer" and "radiotherapy" and "tumour volume" and "prognostic factors".RESULTS: After final consideration 17, 14 and 9 studies with a total of 2516, 784 and 639 patients on predictive impact of GTV, GTV changes and its impact on overall survival, respectively, for definitive radiotherapy for stage III NSCLC were included in this review. Initial GTV is an important prognostic factor for overall survival in several studies, but the time of evaluation and the value of histology need to be further investigated. GTV changes during RT differ widely, optimal timing for re-evaluation of GTV and their predictive value for prognosis needs to be clarified. The prognostic value of GTV changes is unclear due to varying study qualities, re-evaluation time and conflicting results.CONCLUSION: The main findings were that the clinical impact of GTV changes during definitive radiotherapy is still unclear due to heterogeneous study designs with varying quality. Several potential confounding variables were found and need to be considered for future studies to evaluate GTV changes during definitive radiotherapy with respect to treatment outcome.

AB - PURPOSE: Lung cancer remains the leading cause of cancer-related mortality worldwide. Stage III non-small cell lung cancer (NSCLC) includes heterogeneous presentation of the disease including lymph node involvement and large tumour volumes with infiltration of the mediastinum, heart or spine. In the treatment of stage III NSCLC an interdisciplinary approach including radiotherapy is considered standard of care with acceptable toxicity and improved clinical outcome concerning local control. Furthermore, gross tumour volume (GTV) changes during definitive radiotherapy would allow for adaptive replanning which offers normal tissue sparing and dose escalation.METHODS: A literature review was conducted to describe the predictive value of GTV changes during definitive radiotherapy especially focussing on overall survival. The literature search was conducted in a two-step review process using PubMed®/Medline® with the key words "stage III non-small cell lung cancer" and "radiotherapy" and "tumour volume" and "prognostic factors".RESULTS: After final consideration 17, 14 and 9 studies with a total of 2516, 784 and 639 patients on predictive impact of GTV, GTV changes and its impact on overall survival, respectively, for definitive radiotherapy for stage III NSCLC were included in this review. Initial GTV is an important prognostic factor for overall survival in several studies, but the time of evaluation and the value of histology need to be further investigated. GTV changes during RT differ widely, optimal timing for re-evaluation of GTV and their predictive value for prognosis needs to be clarified. The prognostic value of GTV changes is unclear due to varying study qualities, re-evaluation time and conflicting results.CONCLUSION: The main findings were that the clinical impact of GTV changes during definitive radiotherapy is still unclear due to heterogeneous study designs with varying quality. Several potential confounding variables were found and need to be considered for future studies to evaluate GTV changes during definitive radiotherapy with respect to treatment outcome.

KW - Journal Article

U2 - 10.1007/s00066-017-1221-y

DO - 10.1007/s00066-017-1221-y

M3 - SCORING: Review article

C2 - 29030654

VL - 194

SP - 79

EP - 90

JO - STRAHLENTHER ONKOL

JF - STRAHLENTHER ONKOL

SN - 0179-7158

IS - 2

ER -